Compare BLDR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | LEGN |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 2005 | 2020 |
| Metric | BLDR | LEGN |
|---|---|---|
| Price | $73.85 | $20.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | ★ $121.76 | $61.33 |
| AVG Volume (30 Days) | 2.3M | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $0.71 | $42.68 |
| Revenue Next Year | $4.52 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.10 | $16.24 |
| 52 Week High | $151.03 | $38.35 |
| Indicator | BLDR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 40.35 |
| Support Level | $65.10 | $17.01 |
| Resistance Level | $78.13 | $23.80 |
| Average True Range (ATR) | 3.38 | 0.95 |
| MACD | 0.50 | 0.44 |
| Stochastic Oscillator | 73.24 | 50.75 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.